Special Senses & Otolaryngology

Age-related macular degeneration: screening and referral

Clinical Overview and When to Suspect AMD

— Dry (non-exudative, ~85–90%): drusen accumulation, RPE atrophy; slow central vision decline over years; culminates in geographic atrophy.

— Wet (neovascular, ~10–15%): choroidal neovascularization (CNV) with subretinal fluid/hemorrhage; rapid central vision loss over days to weeks; accounts for the majority of severe vision loss.

— Patient ≥55 with gradual blurring of central vision, difficulty reading, faces appearing washed out or distorted.

— Metamorphopsia (straight lines look wavy) — classic for wet AMD.

— Central scotoma, need for brighter light to read, slowed dark adaptation.

— Peripheral vision is preserved — distinguishes from glaucoma and retinitis pigmentosa.

— Age >50, white race, family history (CFH and ARMS2 polymorphisms).

— Smoking — the strongest modifiable risk factor (2–4× risk; cessation reduces progression).

— Hypertension, hyperlipidemia, obesity, low dietary antioxidants/leafy greens, light iris color, chronic UV exposure.

Board pearl: Sudden distortion of straight lines (the bathroom tile grout looks wavy) in a 70-year-old smoker is wet AMD until proven otherwise — same-week ophthalmology referral, because anti-VEGF therapy started within days preserves vision that is otherwise lost permanently.

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults ≥50 in the developed world, driven by progressive degeneration of the retinal pigment epithelium (RPE), Bruch membrane, and photoreceptors at the macula.

Two forms with very different trajectories:

When to suspect in primary care:

Major modifiable and non-modifiable risk factors to elicit:

Step 3 framing: AMD screening is opportunistic, not population-based. USPSTF gives an "I" statement for routine vision screening in asymptomatic older adults — so the FM physician's job is case-finding: ask about visual function at every Medicare wellness visit and refer appropriately.

Presentation Patterns and Key History

— Gradual, bilateral but often asymmetric decline in central vision over months to years.

— Difficulty with fine tasks: reading small print, threading needles, recognizing faces across a room.

— Patients describe needing more light, slow recovery when moving from bright to dim environments (impaired dark adaptation — an early sensitive symptom).

— Late dry AMD (geographic atrophy): dense central scotoma, but no distortion.

— Acute or subacute (days to weeks) onset of central blur, metamorphopsia, or a dark/gray central spot.

— Often unilateral at onset; fellow eye carries ~10%/year risk of conversion if intermediate AMD is present.

— May be discovered only when the patient covers the better eye and notices the bad one.

— Quantify functional impact: driving safety, reading, falls, medication self-administration, depression screening (vision loss → social isolation and PHQ-9 elevation).

— Smoking pack-years and willingness to quit — this is the single most impactful counseling lever.

— Diet history: green leafy vegetables, fish (omega-3), nuts; alcohol use.

— Family history of AMD or "going blind in old age."

— Medication review: chronic high-dose aspirin has weak/mixed association with neovascular AMD but is not a reason to stop indicated cardiovascular aspirin.

— Amsler grid at home — one eye at a time, daily to weekly; new wavy lines or missing squares trigger urgent eye visit.

— Smartphone apps and home OCT (emerging) for high-risk patients.

Step 3 management: At the Medicare Annual Wellness Visit, document a brief functional vision assessment ("Do you have trouble reading, recognizing faces, or driving at night?"). A positive response — even with intact Snellen acuity — warrants referral to optometry or ophthalmology, because central distortion can precede measurable acuity loss by months.

Dry AMD presentation:

Wet AMD presentation:

Key history elements at the FM visit:

Self-monitoring tools to discuss:

Physical Exam Findings on Office and Fundoscopic Assessment

— Test each eye separately with habitual correction or pinhole.

— Early AMD may have 20/20–20/40 acuity yet significant metamorphopsia — acuity alone misses disease.

— Advanced disease: 20/200 or worse centrally.

— Patient holds grid at reading distance, covers one eye, fixates on central dot.

— Positive: wavy lines, missing/blurred squares, dark spot — sensitive for macular pathology.

— Drusen — yellow-white deposits at the macula. Size matters: small (<63 µm) drusen are normal aging; medium (63–124 µm) and large (≥125 µm) define AMD severity.

— RPE changes: hyper-/hypopigmentation, mottling.

— Geographic atrophy: sharply demarcated areas of RPE loss exposing choroidal vessels.

— Wet AMD clues: subretinal hemorrhage, gray-green subretinal membrane, macular edema, exudates, retinal thickening.

— Blood pressure (hypertension accelerates progression).

— Carotid bruits, lipid panel — shared vascular risk profile.

— Gait and Timed Up-and-Go: low-vision patients are fall risks.

Key distinction: AMD pathology is confined to the macula — peripheral retina is normal, and the patient still navigates rooms well. If a patient bumps into furniture or has tunnel vision, think glaucoma or retinitis pigmentosa, not AMD. Conversely, if straight lines look wavy and peripheral vision is intact, the lesion is macular by definition.

Visual acuity (Snellen at 20 feet or handheld near card):

Amsler grid testing in clinic:

Confrontation visual fields: Typically normal peripherally; a central scotoma may be elicited by asking the patient to describe your face while fixating.

Pupillary exam: Pupils and RAPD are typically normal in AMD — a relative afferent pupillary defect points elsewhere (optic neuropathy, large retinal detachment, CRAO).

Direct ophthalmoscopy (dilated when possible):

Hemodynamic/systemic correlates worth checking at the same visit:

Diagnostic Workup — Initial Office Assessment and Imaging

— Best-corrected visual acuity each eye.

— Amsler grid for metamorphopsia/scotoma.

— Dilated fundoscopy if comfortable; otherwise refer.

— No routine labs are indicated for AMD itself, but obtain or update lipid panel, HbA1c, BP, given shared risk factors and the need to rule out diabetic maculopathy.

— Optical coherence tomography (OCT) — the workhorse. Non-invasive cross-sectional retinal imaging. Detects:

– Drusen beneath RPE.

– Intraretinal or subretinal fluid — hallmark of active wet AMD.

– Pigment epithelial detachment (PED).

– Photoreceptor and RPE atrophy in dry AMD.

— Fundus photography — documents drusen burden, RPE changes, hemorrhage; tracks progression over years.

— Fundus autofluorescence (FAF) — maps geographic atrophy by lipofuscin signal.

— Risk factors counted in each eye: (1) ≥1 large druse (≥125 µm), (2) any pigment abnormality.

— Sum across both eyes (0–4) → predicts 5-year risk of advanced AMD: 0 → 0.5%, 1 → 3%, 2 → 12%, 3 → 25%, 4 → 50%.

— Documented monocular acuity, Amsler result, smoking status, BP, lipid panel, medication list including supplements.

Step 3 management: When ordering imaging through ophthalmology, OCT is the single most useful test for distinguishing dry from wet AMD and for guiding anti-VEGF dosing. You don't order it directly, but knowing that OCT findings (subretinal fluid) drive injection decisions helps you counsel the patient about what to expect at their referral visit.

In the primary care office, the "workup" is largely clinical screening plus structured referral. Confirmatory imaging is performed by eye care providers, but the FM physician must know what those tests show and what they decide.

Office-level diagnostics:

First-line imaging by ophthalmology:

Severity classification (AREDS Simplified Severity Scale, per eye):

Pre-referral checklist the family physician should complete:

Diagnostic Workup — Advanced and Confirmatory Studies

— Non-invasive visualization of retinal and choroidal microvasculature; detects choroidal neovascular membranes (CNV) without dye injection.

— Increasingly first-line for suspected wet AMD; useful in patients with contrast allergies or poor renal function.

— Historic gold standard for CNV characterization.

— Identifies classic vs. occult CNV, leakage patterns, polypoidal lesions.

— IV fluorescein — generally safe; warn of transient yellow skin/urine; rare anaphylaxis (~1:200,000).

— Better visualization of choroidal circulation; used for polypoidal choroidal vasculopathy and occult CNV.

— Contains iodine — caution in shellfish/iodine allergy and hepatic dysfunction.

— Not routinely recommended. CFH and ARMS2 polymorphisms confer risk but do not change AMD management; AAO advises against commercial genetic panels outside research.

— Patient <50 with macular drusen → consider pattern dystrophies, Stargardt disease, Best disease — refer to retina specialist for genetic/electrophysiologic workup (ERG, EOG).

— Unilateral hemorrhagic maculopathy in a younger patient → polypoidal choroidal vasculopathy (more common in Asian, African ancestry) or myopic CNV.

— Bilateral macular edema without drusen → diabetic maculopathy, CSR, uveitis, drug toxicity (hydroxychloroquine, tamoxifen).

Board pearl: A 68-year-old with new metamorphopsia, OCT showing subretinal fluid and a pigment epithelial detachment, and FA demonstrating late leakage = neovascular AMD. The single most time-sensitive intervention is intravitreal anti-VEGF within days, not further imaging — delays of even 1–2 weeks measurably worsen final visual acuity.

OCT angiography (OCT-A):

Fluorescein angiography (FA):

Indocyanine green angiography (ICG):

Genetic testing:

Differential workup when the picture is atypical:

AREDS biomarkers beyond drusen: reticular pseudodrusen and impaired dark adaptation (e.g., AdaptDx) identify intermediate AMD patients at highest progression risk; useful for trial enrollment.

Risk Stratification and Referral Logic from Primary Care

— Asymptomatic, no risk factors, age <50 → no specific AMD screening; routine eye exams per general guidance.

— Asymptomatic, age 50–64 → comprehensive eye exam every 2 years (AAO).

— Asymptomatic, age ≥65 → comprehensive eye exam every 1–2 years.

— Known intermediate AMD or family history → eye exam every 6–12 months with home Amsler grid.

— Any new metamorphopsia, central scotoma, or acute central vision loss → urgent referral within 24–72 hours to ophthalmology/retina.

— No/early AMD (small drusen only): observe, lifestyle modification.

— Intermediate AMD (large drusen or non-central geographic atrophy): AREDS2 supplements, smoking cessation, home monitoring.

— Advanced AMD (central GA or neovascular): low-vision rehab ± anti-VEGF.

— Smoking cessation is the highest-yield intervention; document at every visit.

— Optimize BP <130/80, LDL per ASCVD risk, BMI, Mediterranean-style diet.

— Counsel against high-dose beta-carotene supplements in smokers (lung cancer risk in CARET/ATBC trials — relevant to AREDS2 choice).

— Assess fall risk (Timed Up-and-Go ≥12 s), driving fitness, medication safety, depression — all rise sharply in advanced AMD.

Step 3 management: A 72-year-old smoker with large drusen and visual acuity 20/30 has intermediate AMD. Your FM-level orders: (1) refer to ophthalmology for AREDS2 counseling and baseline OCT, (2) prescribe smoking cessation pharmacotherapy (varenicline or combination NRT), (3) provide an Amsler grid with same-day return precautions, (4) review driving safety, (5) schedule 3-month follow-up.

Step 3-style referral algorithm:

AREDS severity-driven stratification (used by ophthalmology, but FM should know):

Stratify systemic risk simultaneously:

Functional risk stratification:

Pharmacotherapy and Supplements — First-Line Regimens

— Indications: intermediate AMD in one or both eyes, or advanced AMD in one eye (to protect the fellow eye). Reduces 5-year risk of progression to advanced AMD by ~25%.

— Not indicated for early AMD or as primary prevention in patients with only small drusen — no benefit shown.

— Vitamin C 500 mg

— Vitamin E 400 IU

— Lutein 10 mg + zeaxanthin 2 mg (replaced beta-carotene)

— Zinc oxide 80 mg (or 25 mg low-dose alternative)

— Cupric oxide 2 mg (to prevent zinc-induced copper deficiency anemia)

— Do not give beta-carotene–containing AREDS formula to current or former smokers — increases lung cancer risk; use the AREDS2 lutein/zeaxanthin version.

— High-dose vitamin E — caution with warfarin (additive bleeding) and avoid in patients with prior hemorrhagic stroke.

— Zinc can cause GI upset and copper-deficiency anemia/myelopathy if copper not co-administered.

— Supplements slow progression; they do not restore vision or prevent dry AMD from starting.

— Intravitreal anti-VEGF agents: bevacizumab (off-label), ranibizumab, aflibercept, brolucizumab, faricimab.

— Typically monthly loading × 3, then treat-and-extend.

— Faricimab (anti-VEGF + anti-Ang-2) and high-dose aflibercept allow longer dosing intervals.

Board pearl: AREDS2 supplements do not prevent AMD — they only slow progression in patients who already have intermediate or unilateral advanced AMD. Prescribing them to a patient with only small drusen is a Step 3 distractor answer.

AREDS2 oral supplement formula — the only evidence-based oral therapy for AMD and a core FM-administered intervention.

AREDS2 daily composition:

Key counseling points:

Wet AMD pharmacotherapy (administered by retina specialists, but tested):

Pegcetacoplan and avacincaptad pegol — newer intravitreal complement inhibitors that slow geographic atrophy progression; do not improve acuity; specialist-driven.

Procedures and Advanced Interventions

— Performed in-office by retina specialist after topical anesthetic and povidone-iodine prep.

— Targets VEGF-driven choroidal neovascularization; stabilizes vision in ~90%, improves vision in ~30%.

— Treat-and-extend regimen: re-image with OCT each visit; extend interval by 2 weeks if dry, shorten if fluid recurs.

— Common agents and intervals:

– Bevacizumab (off-label, cost-effective; CATT trial showed non-inferiority to ranibizumab).

– Ranibizumab 0.5 mg q4 wk → extend.

– Aflibercept 2 mg q4 wk × 3, then q8 wk; high-dose 8 mg allows q12–16 wk.

– Faricimab q4 wk × 4, then up to q16 wk.

— Endophthalmitis (~1:1,000–3,000 per injection) — pain, redness, vision drop within days → emergent retina re-evaluation.

— Retinal detachment, intraocular hemorrhage, transient IOP elevation, traumatic cataract.

— Small systemic stroke/MI signal with anti-VEGF; weigh in patients with recent CVA.

— Intravitreal pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) slow lesion growth ~15–20%; risk of inducing wet AMD conversion.

— Implantable Miniature Telescope (IMT) in select monocular advanced AMD patients ≥65.

— Low-vision rehabilitation with magnifiers, eccentric viewing training, electronic readers.

CCS pearl: A patient on monthly anti-VEGF who presents with acute pain, hypopyon, and vision drop 3 days post-injection — order immediate ophthalmology consult for suspected endophthalmitis; the standard is vitreous tap and intravitreal antibiotics within hours, not next-day clinic.

Intravitreal anti-VEGF injection — the definitive treatment for neovascular (wet) AMD:

Injection-related risks to disclose:

Photodynamic therapy with verteporfin — niche use for polypoidal choroidal vasculopathy and select CNV unresponsive to anti-VEGF.

Thermal laser photocoagulation — largely obsolete for AMD; rare extrafoveal CNV.

Geographic atrophy:

Surgical/device interventions for end-stage AMD:

Special Populations — Elderly and Renal/Hepatic Impairment

— Polypharmacy review: ensure anticoagulants are appropriate; warfarin and DOACs do not need to be stopped for intravitreal injection, but pre-procedure INR should be in range.

— Cognitive screening (Mini-Cog, MoCA) — patients with dementia may not reliably perform Amsler self-monitoring; involve caregivers.

— Fall prevention: vision loss compounds proprioceptive and vestibular decline. Refer to PT for vestibular/balance training; address home lighting, throw rugs, stair markings.

— Driving fitness: most states require corrected acuity ≥20/40 in the better eye; report per state mandatory reporting laws where applicable.

— Depression screening (PHQ-9) at every visit — vision loss doubles depression risk; address with SSRI and low-vision rehab.

— AREDS2 supplements are generally safe in CKD, but high-dose vitamin C can theoretically promote oxalate stones — counsel CKD/stone formers.

— Zinc 80 mg — acceptable in CKD; monitor copper.

— Fluorescein angiography — fluorescein is renally excreted; safe in mild–moderate CKD, caution in dialysis (timing relative to HD).

— ICG — contains iodine and is hepatically processed; avoid in severe hepatic dysfunction and iodine allergy.

— Intravitreal anti-VEGF — minimal systemic exposure; no renal/hepatic dose adjustment needed, but watch for systemic thromboembolic events in fragile patients.

— Discuss whether monthly clinic injections align with patient values; some elderly patients choose less aggressive schedules or decline therapy.

Step 3 management: In an 85-year-old with mild dementia, CKD stage 3, and new wet AMD, refer urgently to retina but co-manage with the caregiver and geriatrics: arrange transportation, simplify the medication list, ensure home Amsler monitoring is delegated, and document a shared decision about injection cadence with quality-of-life goals.

AMD is fundamentally a disease of the elderly — prevalence ~2% at 50, rising to >30% in some form by age 80.

Geriatric-specific considerations:

Renal and hepatic considerations:

Frailty and goals of care:

Special Populations — Younger Adults, Pregnancy, and Ancestry-Based Variants

— Stargardt disease (ABCA4) — autosomal recessive, teens to 30s, central vision loss, flecks on fundus, "dark choroid" on FA.

— Best vitelliform dystrophy (BEST1) — egg-yolk macular lesion, abnormal EOG.

— Pattern dystrophies, Sorsby fundus dystrophy, North Carolina macular dystrophy.

— Drug-induced maculopathy: hydroxychloroquine (bull's-eye), tamoxifen, deferoxamine, pentosan polysulfate.

— Refer to medical retina/genetics, not standard AMD pathway.

— AMD itself is unrelated to pregnancy, but pregnant women with prior wet AMD present a management challenge:

– Anti-VEGF agents are pregnancy category C/avoided — VEGF is essential for placental and fetal vascular development; risk of fetal harm.

– Defer elective injections when possible; if vision-threatening CNV requires treatment, perform shared decision-making with MFM.

— AREDS2 supplements: vitamin A in pregnancy is teratogenic, but AREDS2 uses lutein/zeaxanthin, not retinol-form vitamin A; high-dose vitamin E and zinc should be reviewed with OB.

— Pregnant patients with macular changes are more likely to have central serous chorioretinopathy (CSR) — typically resolves postpartum.

— Polypoidal choroidal vasculopathy (PCV) — more common in patients of East Asian and African descent; presents with recurrent serosanguineous PEDs; ICG-guided diagnosis; responds to anti-VEGF ± PDT.

— Classic drusen-based AMD is most prevalent in White populations; AMD in patients of other ancestries warrants careful evaluation for PCV or alternative diagnoses.

Key distinction: A 35-year-old with bilateral macular flecks and difficulty reading is not AMD — order genetic testing for Stargardt disease. AREDS2 supplements have no role here; refer to inherited retinal disease specialist.

AMD is by definition a disease of those ≥50. Macular disease in younger patients is not AMD and demands a different referral pathway.

Differential in patients <50 with drusen-like macular findings:

Pregnancy considerations:

Ancestry-based variants:

Complications and Adverse Outcomes

— Permanent central scotoma — even with successful anti-VEGF therapy, fibrotic scarring of the CNV can leave a disabling central blind spot.

— Disciform scar — end-stage fibrovascular replacement of the macula; legal blindness in that eye.

— Geographic atrophy progression — relentless even with complement inhibitors; lesion enlargement of ~1.5–2.5 mm²/year.

— Bilateral disease — once one eye has advanced AMD, the fellow eye carries ~7–10%/year progression risk to advanced disease.

— Loss of driving privileges → social isolation, depression, caregiver burden.

— Falls and hip fractures — vision-impaired older adults have 2× the fall rate; falls are a leading cause of mortality after macular vision loss.

— Medication errors — inability to read labels; pill organizers, large-print labels, and pharmacist consultation are protective.

— Charles Bonnet syndrome — formed visual hallucinations (people, flowers, geometric patterns) in cognitively intact patients with severe vision loss. Reassure: not psychosis, not dementia; address by improving ambient lighting and validating the experience.

— Depression — present in up to 30% of advanced AMD patients; treat with SSRI + low-vision rehab.

— Endophthalmitis, retinal detachment, traumatic cataract, sustained IOP elevation from intravitreal injections.

— Geographic atrophy onset/acceleration with complement inhibitor therapy.

— Tachyphylaxis to anti-VEGF in some patients — switching agents may help.

— Treatment burden of monthly injections is substantial; non-adherence leads to worse outcomes; transportation and copay barriers are real.

Board pearl: An 80-year-old with advanced AMD reports vivid hallucinations of small children in her living room. She has intact cognition, no delirium, and insight that the images aren't real. This is Charles Bonnet syndrome — reassure and optimize lighting; do not start antipsychotics and do not order a stroke workup.

Visual complications:

Functional and psychosocial complications:

Treatment-related complications:

Health-system complications:

When to Escalate Care — Urgent Referral Pathways

— Acute central vision loss in an older patient.

— New metamorphopsia or central scotoma — assume neovascular AMD until proven otherwise.

— Subretinal hemorrhage seen on fundoscopy.

— Post-intravitreal injection: pain, redness, decreased vision, photophobia, hypopyon → suspected endophthalmitis, an ocular emergency requiring vitreous tap and intravitreal antibiotics within hours.

— Sudden floaters, flashes, or curtain of vision loss → rule out retinal detachment (independent emergency).

— Newly diagnosed intermediate AMD on routine exam.

— Progression of drusen burden or new pigment changes.

— Patient struggling with home Amsler interpretation.

— Stable dry AMD with established AREDS2 regimen.

— Annual low-vision rehab assessment.

— Low-vision rehabilitation/occupational therapy for any patient with bilateral acuity <20/40 or significant central scotoma.

— Social work for transportation, in-home support, and disability paperwork.

— Geriatrics for frail elders with polypharmacy and fall risk.

— Psychiatry/behavioral health for depression unresponsive to first-line SSRI.

— Most state Medicaid and Medicare plans cover anti-VEGF; bevacizumab is far cheaper than branded agents — relevant to value-based care discussions but clinical equipoise per CATT trial supports use.

CCS pearl: When a Step 3 CCS case presents a post-injection patient with eye pain and worsening vision at 48 hours, do not order outpatient follow-up. The correct sequence: call ophthalmology/retina now, advance the clock to ED or eye ER, anticipate vitreous tap with intravitreal vancomycin + ceftazidime.

AMD does not typically require ICU or inpatient admission, but escalation pathways are critical and frequently tested.

Same-day or 24-hour ophthalmology/retina referral:

Within 1–2 weeks:

Routine (1–3 months):

Other specialists to engage:

Health-system considerations:

Key Differentials — Other Macular and Retinal Causes

— Older diabetic with declining central vision; OCT shows intraretinal cystoid edema; microaneurysms, hard exudates, dot-blot hemorrhages on fundoscopy.

— Management: anti-VEGF or focal laser; tight glycemic and BP control.

— Key distinction: drusen are absent; diabetes history is the clue.

— Younger men (30–50), often with type A personality, exogenous steroid use, or pregnancy.

— Acute blurred central vision, mild metamorphopsia, dome of subretinal fluid on OCT without drusen or hemorrhage.

— Often self-limited; discontinue steroids; refer.

— Older women; sudden central scotoma; OCT shows full-thickness retinal defect at fovea.

— Watzke-Allen sign positive; vitrectomy curative.

— Slow distortion and blur; OCT shows a thin reflective membrane on the inner retina; surgical peel if symptomatic.

— Distortion and decreased vision; OCT shows attached posterior hyaloid pulling on the fovea.

— Decreased vision 4–12 weeks post cataract surgery; topical NSAIDs/steroids.

— Hydroxychloroquine — bull's-eye maculopathy; risk rises after 5 years or cumulative dose; screen with OCT, automated visual fields, fundus autofluorescence annually per AAO.

— Tamoxifen — refractile deposits; usually asymptomatic.

— Pentosan polysulfate (Elmiron) — pigmentary maculopathy in long-term users for interstitial cystitis.

Key distinction: Drusen distinguish AMD from nearly every other macular cause. If the OCT shows macular edema without drusen, your differential pivots to diabetic maculopathy, CSR, vein occlusion, or drug toxicity — not AMD.

Within the "macular pathology" category, several mimics share central vision symptoms:

Diabetic macular edema (DME):

Central serous chorioretinopathy (CSR):

Macular hole:

Epiretinal membrane (macular pucker):

Vitreomacular traction:

Cystoid macular edema (post-cataract — Irvine-Gass syndrome):

Toxic maculopathies:

Key Differentials — Non-Macular Causes of Vision Loss in the Elderly

— Gradual painless decline, glare, halos around lights, reduced contrast.

— Lens opacity on slit lamp; no metamorphopsia; no central scotoma.

— Treatment: phacoemulsification — restores vision even with concomitant AMD (though AMD limits final acuity).

— Insidious peripheral visual field loss, eventually tunnel vision.

— Cupped optic disc, elevated IOP, normal central vision until late.

— Key distinction from AMD: AMD spares periphery; glaucoma spares center.

— Floaters, vitreous hemorrhage, neovascularization at the disc.

— Fundoscopy: dot-blot hemorrhages, cotton-wool spots, NVD/NVE.

— Sudden painless monocular vision loss; "blood and thunder" fundus in CRVO; BP, diabetes, hyperviscosity workup.

— Sudden painless vision loss within seconds; cherry-red spot; an ocular stroke — workup includes carotid Doppler, ECG, echocardiogram, GCA evaluation in those ≥50.

— Age ≥50, headache, jaw claudication, scalp tenderness, PMR symptoms, elevated ESR/CRP.

— Start high-dose IV/oral steroids immediately; do not wait for biopsy.

— RAPD, color desaturation, neurologic signs — point to optic nerve or CNS, not macula.

Step 3 management: Sudden painless monocular vision loss in a 75-year-old with new headache and jaw pain is GCA-related AION, not AMD. Order stat ESR/CRP, start IV methylprednisolone 1 g daily ×3 days, and arrange temporal artery biopsy within 1–2 weeks — steroids should not be delayed.

Older patients with vision complaints often have multiple coexisting eye diseases; sorting them is high yield.

Cataract:

Primary open-angle glaucoma:

Diabetic retinopathy (non-macular):

Retinal vein occlusion (CRVO/BRVO):

Retinal artery occlusion (CRAO):

Giant cell arteritis (anterior ischemic optic neuropathy):

Optic neuritis, ischemic optic neuropathy, stroke (homonymous defects):

Refractive error / presbyopia — easily corrected; always do a pinhole test.

Secondary Prevention and Long-Term Management Plan

— Smoking cessation — counsel at every visit; offer varenicline, bupropion, or combination NRT; refer to quitline. Risk reduction begins within years of cessation.

— AREDS2 supplementation for intermediate or unilateral advanced AMD: lutein 10/zeaxanthin 2, vitamins C 500 mg, E 400 IU, zinc 80 mg, copper 2 mg. Avoid beta-carotene in smokers.

— Mediterranean-style diet: leafy greens (kale, spinach — natural lutein/zeaxanthin), fatty fish 2×/week (omega-3s), nuts, olive oil, limited red meat. Observational data support reduced progression.

— Cardiovascular optimization: BP <130/80, statin for ASCVD per ACC/AHA, HbA1c <7% if diabetic, weight management, exercise 150 min/week.

— UV protection: sunglasses with UV400; brimmed hats — biologically plausible, low cost.

— Reconcile OTC supplements — many "eye health" products lack AREDS2 dosing or contain unnecessary additives.

— Ensure copper is co-prescribed with high-dose zinc.

— Aspirin for established ASCVD: continue despite weak association with neovascular AMD; cardiovascular benefit outweighs ocular risk.

— Anticoagulation: continue as indicated; intravitreal injections are safe on warfarin/DOACs with INR in range.

— Daily Amsler grid for each eye; alternative: ForeseeHome (Medicare-covered home monitoring device for intermediate AMD).

— Patient should know red-flag symptoms warranting same-week eye visit: new distortion, central blind spot, sudden blur.

— Influenza, pneumococcal, RSV, shingles, COVID-19 boosters — vision-impaired elders are at increased respiratory illness morbidity.

Board pearl: The single most powerful modifiable intervention to slow AMD progression is smoking cessation — outweighs AREDS2 supplements in absolute risk reduction. On Step 3, "advise smoking cessation" is rarely the wrong answer in an AMD vignette with a smoker.

Cornerstones of AMD secondary prevention:

Pharmacologic considerations to revisit at every primary care visit:

Home monitoring:

Vaccination and general health maintenance:

Follow-Up, Monitoring, and Rehabilitation

— Early AMD: comprehensive eye exam every 1–2 years; home Amsler weekly.

— Intermediate AMD: ophthalmology every 6–12 months; daily Amsler; consider ForeseeHome.

— Advanced AMD (dry/GA): ophthalmology every 6 months; low-vision rehab.

— Wet AMD on anti-VEGF: retina every 4–12 weeks per treat-and-extend; FM coordinates transportation, copay assistance.

— Snellen acuity, Amsler grid, BP, weight, smoking status, depression screen — at every visit.

— Annual lipid panel, HbA1c if diabetic.

— Medication reconciliation, especially AREDS2 adherence and copper.

— Functional assessment: driving, reading, falls, medication management, social engagement.

— Components: magnifiers, CCTV/electronic readers, eccentric viewing training, lighting optimization, smartphone accessibility (VoiceOver, magnification), audiobooks, large-print materials.

— Occupational therapy for home safety assessment: lighting, contrast strips on stairs, removal of throw rugs.

— Orientation and mobility training, white cane use for advanced disease.

— Most states require 20/40 best-corrected vision in the better eye and adequate visual fields.

— Bioptic telescopes legal in some states.

— Refer to on-road driving evaluation when in doubt; document the conversation.

— Connect to American Macular Degeneration Foundation, AAO EyeSmart, state agencies for the blind.

— Address depression, social isolation, transportation barriers.

Step 3 management: A 78-year-old with bilateral advanced AMD (20/100 each eye), worsening depression, and recent fall. Orders: referral to low-vision rehab and occupational therapy for home safety, start sertraline 25 mg daily after PHQ-9, PT for balance training, driving cessation discussion, social work for transportation and meal services, follow up in 4 weeks.

Follow-up cadence by AMD stage (FM coordinates; ophthalmology executes):

Monitoring parameters in the FM office:

Low-vision rehabilitation — frequently undertilized; refer if bilateral acuity ≤20/40, central scotoma, or functional impairment.

Driving counseling:

Caregiver and social supports:

Ethical, Legal, and Patient Safety Considerations

— Patients must understand the indefinite, often lifelong nature of treatment; risks of endophthalmitis, retinal detachment, traumatic cataract, and small systemic stroke/MI signal; alternatives including observation.

— Off-label bevacizumab: explicit disclosure that it is FDA-approved for oncology, used off-label for AMD with strong evidence (CATT trial); patient may decline in favor of FDA-approved agents at higher cost.

— State laws vary. Some states (e.g., California, Pennsylvania, Oregon) require physicians to report drivers with vision impairment below threshold to the DMV.

— Document the conversation, the patient's response, and whether reporting was made.

— In non-mandatory states, physicians retain a duty to counsel and document, and may report under permissive statutes if the patient continues to drive unsafely.

— Balance patient autonomy against public safety — a tested Step 3 ethics theme.

— Elderly AMD patients with mild cognitive impairment may still have capacity to consent for treatment; assess decision-specific capacity (understanding, appreciation, reasoning, expression of choice).

— Engage healthcare proxies and advance directives early.

— Anti-VEGF injection schedules are easily disrupted by hospitalization, transfer to SNF, or new caregivers — missed injections lead to permanent vision loss. Medication reconciliation at discharge must include injection schedules, not just oral medications.

— Coordinate retina specialist appointments before discharge.

— Cost of branded anti-VEGFs is substantial; offer bevacizumab when clinically appropriate; connect with patient assistance programs.

— Transportation, language barriers, and rural access reduce treatment adherence — actively address.

— Do not prescribe AREDS formula with beta-carotene to current/former smokers — documented lung cancer risk.

— Avoid unnecessary supplements and "vision vitamins" with unproven combinations.

Board pearl: A 76-year-old driver with bilateral acuity 20/80 insists on continuing to drive. Your duties: counsel against driving, document, refer for on-road evaluation, and report to DMV if required by state law. Failure to do so is a tested malpractice/public safety scenario.

Informed consent for intravitreal injections:

Driving and mandatory reporting:

Capacity and shared decision-making:

Transitions of care:

Health equity and access:

Avoiding harm:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Peripheral vision intact + central distortion = AMD; central vision intact + peripheral loss = glaucoma; sudden painless vision loss + cherry-red spot = CRAO (ocular stroke).

Leading cause of irreversible central vision loss in adults ≥50 in industrialized nations.

85–90% dry, 10–15% wet — but wet AMD causes the majority of severe vision loss.

Strongest modifiable risk factor: smoking. Strongest non-modifiable: age, then family history (CFH, ARMS2).

Drusen = extracellular deposits between RPE and Bruch membrane; hard small drusen = normal aging; large soft drusen = AMD.

Metamorphopsia = think macula; classic for wet AMD.

Amsler grid = patient's home self-monitoring tool.

OCT = first-line imaging; subretinal/intraretinal fluid = active wet AMD.

AREDS2 (lutein/zeaxanthin replaced beta-carotene): only for intermediate or unilateral advanced AMD, not for prevention.

No beta-carotene in smokers (CARET/ATBC lung cancer risk).

Anti-VEGF intravitreal injections = standard of care for wet AMD; bevacizumab non-inferior to ranibizumab per CATT trial.

Pegcetacoplan / avacincaptad pegol = complement inhibitors that slow geographic atrophy (don't restore vision).

Charles Bonnet syndrome = formed hallucinations in vision-impaired cognitively intact elderly — reassure, not psychosis.

Endophthalmitis post-injection = pain, redness, vision loss within days → vitreous tap + intravitreal antibiotics.

Hydroxychloroquine maculopathy = bull's-eye; screen with OCT, HVF 10-2, FAF annually after 5 years.

Polypoidal choroidal vasculopathy = Asian/African ancestry, recurrent serosanguineous PEDs, ICG-diagnosed.

Stargardt disease (ABCA4): drusen-like flecks in patient <40 — not AMD.

CSR: type-A male, steroid use, subretinal fluid without drusen, often self-resolves.

Legal blindness in US: best-corrected acuity ≤20/200 or visual field ≤20° in better eye.

USPSTF: "I" statement on routine vision screening in asymptomatic older adults — practice case-finding.

AAO recommends comprehensive eye exam every 1–2 years for adults ≥65.

Board Question Stem Patterns

— A 72-year-old smoker reports that over the past week, straight lines on his bathroom tiles appear wavy and there's a "gray spot" in the center of his right eye. Snellen 20/60 OD, 20/30 OS.

— Next step: Urgent referral to retina/ophthalmology; expect OCT showing subretinal fluid and initiation of anti-VEGF therapy.

— A 68-year-old with bilateral medium and large drusen, no neovascularization, acuity 20/30. What supplement reduces progression?

— Answer: AREDS2 (lutein/zeaxanthin, vitamins C and E, zinc, copper). Beta-carotene avoided due to smoking.

— Patient 2 days post-anti-VEGF presents with eye pain, redness, hypopyon, vision drop.

— Diagnosis: Endophthalmitis. Next step: Same-day retina referral for vitreous tap and intravitreal antibiotics.

— 82-year-old with advanced AMD describes seeing small children and flowers, knows they are not real, has intact cognition.

— Diagnosis: Charles Bonnet. Management: Reassurance, optimize lighting; avoid antipsychotics.

— 75-year-old with sudden monocular vision loss, headache, jaw claudication, ESR 95.

— Diagnosis: GCA-related AION. Next step: High-dose IV steroids immediately, temporal artery biopsy within 1–2 weeks.

— 32-year-old with bilateral central blur, macular flecks, "dark choroid" on FA.

— Diagnosis: Stargardt disease. AREDS2 not indicated; genetics referral.

— Patient with bilateral 20/100 AMD insists on driving.

— Best response: Counsel cessation, document, refer for on-road evaluation, report to DMV per state law.

— 65-year-old asymptomatic, no risk factors. Which screening test?

— Answer: Comprehensive eye exam every 1–2 years (not routine in-office acuity screening, given USPSTF "I").

Step 3 management: Recognize the "smoker + new metamorphopsia + central scotoma" triad as urgent neovascular AMD — the high-yield reflex referral that saves vision.

Stem 1 — Classic wet AMD presentation:

Stem 2 — AREDS2 indications:

Stem 3 — Post-injection complication:

Stem 4 — Charles Bonnet syndrome:

Stem 5 — Differential trap:

Stem 6 — Younger patient with maculopathy:

Stem 7 — Driving and ethics:

Stem 8 — Health maintenance distractor:

One-Line Recap

AMD is an age-driven degeneration of the macula presenting as drusen with gradual central vision loss (dry) or acute metamorphopsia from choroidal neovascularization (wet), where the primary care physician's job is risk-factor modification — especially smoking cessation — AREDS2 supplementation for intermediate disease, structured home Amsler monitoring, and same-week referral of any new distortion or central scotoma to a retina specialist for OCT and intravitreal anti-VEGF therapy.

High-yield recap bullets:

Board pearl: On Step 3, the right answer is almost always (1) refer urgently for acute distortion, (2) AREDS2 + smoking cessation for intermediate disease, (3) low-vision rehab + depression screen for advanced disease, and (4) document driving fitness and state-mandated reporting when acuity falls below threshold.

Suspect wet AMD in any patient ≥50 with new metamorphopsia or central scotoma → urgent (≤72-hour) ophthalmology referral; anti-VEGF within days preserves vision.

AREDS2 supplements (lutein/zeaxanthin, vitamins C and E, zinc, copper — no beta-carotene in smokers) are indicated only for intermediate AMD or unilateral advanced AMD, not for primary prevention or early disease.

Smoking cessation is the single most impactful modifiable intervention — counsel and pharmacotherapy at every visit; combine with Mediterranean diet, BP and lipid control, and UV protection.

Coordinate the longitudinal team: ophthalmology/retina for injections and OCT, low-vision rehabilitation and occupational therapy for bilateral acuity ≤20/40 or central scotoma, social work for transportation/copay, and explicit driving and depression assessments — recognizing Charles Bonnet syndrome (formed hallucinations in cognitively intact vision-impaired elders) as a benign phenomenon requiring reassurance, not antipsychotics.